44 results
8-K
EX-99.1
ZLAB
Zai Lab Limited
8 May 24
Zai Lab Announces First Quarter 2024
4:09pm
and the oral formulation for these indications in the first quarter of 2024.
Research and Development (R&D) expenses were $54.6 million in the first quarter
8-K
EX-99.1
ZLAB
Zai Lab Limited
27 Feb 24
Zai Lab Announces Full-Year 2023
4:12pm
to the NRDL for these indications, effective January 1, 2024, which we expect to further increase patient access.
Research and Development (R&D) expenses were
8-K
EX-99.1
ur5vga92kdhr7kzegf
7 Nov 23
Zai Lab Announces Third Quarter 2023
4:10pm
8-K
EX-99.1
kp1 nqt74i
7 Aug 23
Zai Lab Announces Second Quarter 2023
4:07pm
8-K
EX-99.1
g1tk6nrl3sl q3e
9 May 23
Zai Lab Announces First Quarter 2023
4:03pm
8-K
EX-99.1
whmg uc0y0
9 Nov 22
Zai Lab Announces Third Quarter 2022
4:13pm
8-K
EX-99.1
ackunkxse
9 Aug 22
Zai Lab Announces Second Quarter 2022
12:00am
8-K
EX-99.1
4qoju0
10 May 22
Zai Lab Announces First Quarter 2022
4:10pm
8-K
EX-99.1
y0as5c
1 Mar 22
Results of Operations and Financial Condition
4:17pm
8-K
4vle hez9pbh
22 Nov 21
Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors
7:40am
8-K
EX-99.3
2y7ocj0 k39
9 Nov 21
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License
4:26pm